Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Bought by Point72 Asset Management L.P.

Point72 Asset Management L.P. boosted its stake in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 155.9% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 947,570 shares of the company's stock after buying an additional 577,220 shares during the quarter. Point72 Asset Management L.P. owned approximately 2.34% of Keros Therapeutics worth $55,025,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Keros Therapeutics by 26.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company's stock valued at $77,000 after buying an additional 280 shares during the period. KBC Group NV increased its stake in Keros Therapeutics by 52.0% in the third quarter. KBC Group NV now owns 1,263 shares of the company's stock valued at $73,000 after purchasing an additional 432 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. lifted its position in Keros Therapeutics by 36.7% during the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,844 shares of the company's stock worth $223,000 after buying an additional 1,033 shares during the period. Arizona State Retirement System grew its holdings in Keros Therapeutics by 16.3% in the 2nd quarter. Arizona State Retirement System now owns 8,077 shares of the company's stock valued at $369,000 after buying an additional 1,130 shares during the period. Finally, Algert Global LLC grew its holdings in Keros Therapeutics by 10.6% in the second quarter. Algert Global LLC now owns 15,700 shares of the company's stock valued at $717,000 after purchasing an additional 1,505 shares during the period. Institutional investors and hedge funds own 71.56% of the company's stock.

Keros Therapeutics Trading Down 4.7 %

KROS stock traded down $3.18 during mid-day trading on Thursday, hitting $64.61. 591,800 shares of the company were exchanged, compared to its average volume of 376,370. The firm has a fifty day simple moving average of $60.05 and a 200 day simple moving average of $52.56. The company has a market capitalization of $2.62 billion, a PE ratio of -12.40 and a beta of 1.20. Keros Therapeutics, Inc. has a twelve month low of $27.31 and a twelve month high of $73.00.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The company had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The business's revenue was up 4750.0% on a year-over-year basis. During the same quarter last year, the firm earned ($1.33) earnings per share. As a group, sell-side analysts anticipate that Keros Therapeutics, Inc. will post -5.28 earnings per share for the current year.

Analyst Ratings Changes

KROS has been the topic of a number of research analyst reports. HC Wainwright reiterated a "buy" rating and issued a $100.00 target price on shares of Keros Therapeutics in a report on Thursday, November 7th. Scotiabank began coverage on shares of Keros Therapeutics in a research report on Wednesday, October 16th. They set a "sector outperform" rating and a $77.00 price target on the stock. Cantor Fitzgerald reissued an "overweight" rating on shares of Keros Therapeutics in a research report on Friday, November 22nd. Guggenheim restated a "buy" rating and set a $102.00 target price (up previously from $96.00) on shares of Keros Therapeutics in a report on Wednesday. Finally, Jefferies Financial Group started coverage on Keros Therapeutics in a report on Tuesday, November 5th. They issued a "buy" rating for the company. Twelve investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $89.56.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.